MX2022016101A - Vector. - Google Patents

Vector.

Info

Publication number
MX2022016101A
MX2022016101A MX2022016101A MX2022016101A MX2022016101A MX 2022016101 A MX2022016101 A MX 2022016101A MX 2022016101 A MX2022016101 A MX 2022016101A MX 2022016101 A MX2022016101 A MX 2022016101A MX 2022016101 A MX2022016101 A MX 2022016101A
Authority
MX
Mexico
Prior art keywords
nucleotide sequence
viral vector
vector
podocyte
podocytes
Prior art date
Application number
MX2022016101A
Other languages
English (en)
Spanish (es)
Inventor
Chris Hollowood
Lukas Stanczuk
Moin Ahson Saleem-Uddin
Gavin Iain Welsh
Dominic Schmidt
Valeryia Kuzmuk
Alan William Griffith
Original Assignee
Syncona Investment Man Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncona Investment Man Limited filed Critical Syncona Investment Man Limited
Publication of MX2022016101A publication Critical patent/MX2022016101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Image Analysis (AREA)
  • Devices For Executing Special Programs (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022016101A 2020-06-30 2021-06-30 Vector. MX2022016101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2010009.5A GB202010009D0 (en) 2020-06-30 2020-06-30 Vector
PCT/GB2021/051668 WO2022003357A1 (en) 2020-06-30 2021-06-30 Vector

Publications (1)

Publication Number Publication Date
MX2022016101A true MX2022016101A (es) 2023-06-01

Family

ID=71949697

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016101A MX2022016101A (es) 2020-06-30 2021-06-30 Vector.

Country Status (12)

Country Link
US (1) US20230175016A1 (enExample)
EP (1) EP4172345A1 (enExample)
JP (1) JP2023536008A (enExample)
KR (1) KR20230056658A (enExample)
CN (1) CN115997025A (enExample)
AU (1) AU2021300616A1 (enExample)
BR (1) BR112022026521A2 (enExample)
CA (1) CA3183830A1 (enExample)
GB (1) GB202010009D0 (enExample)
IL (1) IL299505A (enExample)
MX (1) MX2022016101A (enExample)
WO (1) WO2022003357A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
WO2021257480A2 (en) 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods
GB202217332D0 (en) * 2022-11-18 2023-01-04 Univ Bristol Methods
EP4410988A1 (en) * 2023-01-31 2024-08-07 Universitätsklinikum Hamburg-Eppendorf An aav2-vector variant for targeted transfer of genes
EP4669359A1 (en) * 2023-02-21 2025-12-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education MAFB PROMOTER FOR GENE THERAPY FOR DIABETES
GB202304841D0 (en) * 2023-03-31 2023-05-17 Purespring Therapeutics Ltd Promoter
CN121013858A (zh) * 2023-04-27 2025-11-25 俄勒冈健康与科学大学 靶向肾脏的aav衣壳及其使用方法
GB202414499D0 (en) * 2024-10-02 2024-11-13 Purespring Therapeutics Ltd Methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US20050169914A1 (en) * 2003-08-01 2005-08-04 Colgan Sean P. Novel functions for decay accelerating factor (DAF) in inflammation
US7745389B2 (en) * 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
EP2730282A1 (en) * 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP3795581A3 (en) * 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
EP3359663A4 (en) * 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
US12653168B2 (en) * 2018-09-13 2026-06-16 Regeneron Pharmaceuticals, Inc. Complement factor H gene knockout rat as a model of C3 glomerulopathy

Also Published As

Publication number Publication date
AU2021300616A1 (en) 2023-01-19
EP4172345A1 (en) 2023-05-03
CA3183830A1 (en) 2022-01-06
IL299505A (en) 2023-02-01
US20230175016A1 (en) 2023-06-08
JP2023536008A (ja) 2023-08-22
CN115997025A (zh) 2023-04-21
GB202010009D0 (en) 2020-08-12
WO2022003357A1 (en) 2022-01-06
BR112022026521A2 (pt) 2023-01-31
KR20230056658A (ko) 2023-04-27

Similar Documents

Publication Publication Date Title
PH12021552979A1 (en) Viral vectors and their use in adoptive cellular therapy
PH12020550525A1 (en) Novel, highly active amino-thiazole substituted indole-2carboxamides active against the hepatitis b virus (hbv)
MY200994A (en) Mutant P-Hydroxyphenylpyruvate Dioxygenase, Nucleic Acid Encoding the Same and use Thereof
EA202190889A1 (ru) Клостридиальные нейротоксины, содержащие экзогенную петлю активации
PH12021500047A1 (en) Novel indole-2-carboxamides active against the hepatitis b virus (hbv)
EA201290572A1 (ru) Растения, устойчивые к гербицидам - ингибиторам hppd
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
PH12021550970A1 (en) 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
BR112022026521A2 (pt) Vetor viral, célula isolada, composição farmacêutica, uso de um vetor viral, método, e, método para prevenir ou tratar uma doença renal
PH12021550979A1 (en) Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2- carboxamides active against the hepatitis b virus (hbv)
KR100469936B1 (ko) 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
ZA202304290B (en) Nucleic acid constructs, viral vectors and viral particles
PH12021550971A1 (en) Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv)
MX2022006534A (es) Daao modificada y el uso de la misma.
BR112018068890A2 (pt) dna polimerases marinhas
MX2021001901A (es) Nucleotidos de codificacion del factor ix.
EP4282960A3 (en) Modified lipase and use thereof
MX2022001561A (es) Ensayos de potencia para la produccion de vectores virales.
ZA202101156B (en) New attenuated virus strain and use thereof as a vaccine
ATE477322T1 (de) Dna-polymerasen aus thermus eggertssonii
WO2022081728A3 (en) Modified interleukin 2 (il-2) polypeptides, and methods of making and using the same
PH12021552749A1 (en) Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)
PH12021550978A1 (en) Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
WO2022118227A8 (en) Self-replicating rna and uses thereof
PH12021550977A1 (en) Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv)